APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Coagulation Factor Ⅷ for Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Coagulation Factor Ⅷ for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025193 pages

Choose your research edition.

Industry ResearchRecombinant Coagulation Factor Ⅷ for Injection Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Coagulation Factor Ⅷ for Injection Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Recombinant Coagulation Factor Ⅷ for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Coagulation Factor Ⅷ for Injection Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Coagulation Factor Ⅷ for Injection Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Coagulation Factor Ⅷ for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Coagulation Factor Ⅷ for Injection include GC Pharma, Novo Nordisk A/S, SinoCell Tech, Baxter, Bayer, Hualan Biological, Pfizer, Shanghai Raas Corp and Shanghai Xinxing Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Coagulation Factor Ⅷ for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Coagulation Factor Ⅷ for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Coagulation Factor Ⅷ for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Coagulation Factor Ⅷ for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Coagulation Factor Ⅷ for Injection Segment by Company

GC Pharma

Novo Nordisk A/S

SinoCell Tech

Baxter

Bayer

Hualan Biological

Pfizer

Shanghai Raas Corp

Shanghai Xinxing Medicine

Shandong Taibang Biological Products

Recombinant Coagulation Factor Ⅷ for Injection Segment by Type

250 IU/Bottle

500 IU/Bottle

1000 IU/Bottle

2000 IU/Bottle

Recombinant Coagulation Factor Ⅷ for Injection Segment by Application

Hospital

Clinic

Others

Recombinant Coagulation Factor Ⅷ for Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factor Ⅷ for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factor Ⅷ for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factor Ⅷ for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Coagulation Factor Ⅷ for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Coagulation Factor Ⅷ for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Coagulation Factor Ⅷ for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Coagulation Factor Ⅷ for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Coagulation Factor Ⅷ for Injection Industry Trends Table 2. Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers Table 3. Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges Table 4. Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints Table 5. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Manufacturers (Units) & (2021-2026) Table 8. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Manufacturers Table 9. Global Recombinant Coagulation Factor Ⅷ for Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Coagulation Factor Ⅷ for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers, Product Type & Application Table 13. Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Coagulation Factor Ⅷ for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 250 IU/Bottle Table 17. Major Manufacturers of 500 IU/Bottle Table 18. Major Manufacturers of 1000 IU/Bottle Table 19. Major Manufacturers of 2000 IU/Bottle Table 20. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2026) & (Units) Table 22. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2027-2032) & (Units) Table 23. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2026) Table 24. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2027-2032) Table 25. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 26. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2026) & (Units) Table 27. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2027-2032) & (Units) Table 28. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2026) Table 29. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application 2021 VS 2025 VS 2032 (Units) Table 34. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2026) & (Units) Table 35. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2027-2032) & (Units) Table 36. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2026) Table 37. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2027-2032) Table 38. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 39. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2026) & (Units) Table 40. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2027-2032) & (Units) Table 41. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2026) Table 42. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2027-2032) Table 43. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 44. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2026) & (Units) Table 45. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Region (2021-2026) Table 46. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Forecasted by Region (2027-2032) & (Units) Table 47. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 49. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 50. North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 51. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 52. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 53. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 54. Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 56. Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 57. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 58. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2026) & (Units) Table 59. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2027-2032) & (Units) Table 60. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2021-2026) Table 64. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2027-2032) Table 65. GC Pharma Company Information Table 66. GC Pharma Business Overview Table 67. GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 69. GC Pharma Recent Development Table 70. Novo Nordisk A/S Company Information Table 71. Novo Nordisk A/S Business Overview Table 72. Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 74. Novo Nordisk A/S Recent Development Table 75. SinoCell Tech Company Information Table 76. SinoCell Tech Business Overview Table 77. SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 79. SinoCell Tech Recent Development Table 80. Baxter Company Information Table 81. Baxter Business Overview Table 82. Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 84. Baxter Recent Development Table 85. Bayer Company Information Table 86. Bayer Business Overview Table 87. Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 89. Bayer Recent Development Table 90. Hualan Biological Company Information Table 91. Hualan Biological Business Overview Table 92. Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 94. Hualan Biological Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 99. Pfizer Recent Development Table 100. Shanghai Raas Corp Company Information Table 101. Shanghai Raas Corp Business Overview Table 102. Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 104. Shanghai Raas Corp Recent Development Table 105. Shanghai Xinxing Medicine Company Information Table 106. Shanghai Xinxing Medicine Business Overview Table 107. Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 109. Shanghai Xinxing Medicine Recent Development Table 110. Shandong Taibang Biological Products Company Information Table 111. Shandong Taibang Biological Products Business Overview Table 112. Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio Table 114. Shandong Taibang Biological Products Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Recombinant Coagulation Factor Ⅷ for Injection Distributors List Table 118. Recombinant Coagulation Factor Ⅷ for Injection Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Recombinant Coagulation Factor Ⅷ for Injection Product Image Figure 2. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Coagulation Factor Ⅷ for Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Coagulation Factor Ⅷ for Injection Sales (2021-2032) & (Units) Figure 5. Global Recombinant Coagulation Factor Ⅷ for Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Coagulation Factor Ⅷ for Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 250 IU/Bottle Image Figure 9. 500 IU/Bottle Image Figure 10. 1000 IU/Bottle Image Figure 11. 2000 IU/Bottle Image Figure 12. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2032) Figure 15. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 16. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 22. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2032) Figure 24. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 25. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2032) Figure 27. North America Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 28. North America Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Country (2021-2032) Figure 29. U.S. Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 30. Canada Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 31. Mexico Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 32. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 33. Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Country (2021-2032) Figure 34. Germany Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 35. France Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 36. U.K. Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 37. Italy Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 38. Netherlands Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 39. Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 40. Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Country (2021-2032) Figure 41. China Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 42. Japan Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 43. South Korea Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 44. Southeast Asia Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 45. India Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 46. Australia Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 47. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 48. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Country (2021-2032) Figure 49. Brazil Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 50. South Africa Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 51. Saudi Arabia Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 52. Turkey Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 53. Argentina Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 54. UAE Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 55. Egypt Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 56. Chile Recombinant Coagulation Factor Ⅷ for Injection Sales and Growth Rate (2021-2032) & (Units) Figure 57. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Figure 60. North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Figure 62. Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Recombinant Coagulation Factor Ⅷ for Injection Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Recombinant Coagulation Factor Ⅷ for Injection Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 250 IU/Bottle
  • 500 IU/Bottle
  • 1000 IU/Bottle
  • 2000 IU/Bottle
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • GC Pharma
  • Novo Nordisk A/S
  • SinoCell Tech
  • Baxter
  • Bayer
  • Hualan Biological
  • Pfizer
  • Shanghai Raas Corp
  • Shanghai Xinxing Medicine
  • Shandong Taibang Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Coagulation Factor Ⅷ for Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Coagulation Factor Ⅷ for Injection Market Dynamics
  1. 2.1 Recombinant Coagulation Factor Ⅷ for Injection Industry Trends
  2. 2.2 Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers
  3. 2.3 Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges
  4. 2.4 Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints
3 Recombinant Coagulation Factor Ⅷ for Injection Market by Manufacturers
  1. 3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Coagulation Factor Ⅷ for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Coagulation Factor Ⅷ for Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Coagulation Factor Ⅷ for Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Coagulation Factor Ⅷ for Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Coagulation Factor Ⅷ for Injection Tier 1, Tier 2, and Tier 3
4 Recombinant Coagulation Factor Ⅷ for Injection Market by Type
  1. 4.1 Recombinant Coagulation Factor Ⅷ for Injection Type Introduction
  2. 4.1.1 250 IU/Bottle
  3. 4.1.2 500 IU/Bottle
  4. 4.1.3 1000 IU/Bottle
  5. 4.1.4 2000 IU/Bottle
  6. 4.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type
  7. 4.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
  9. 4.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2032)
  10. 4.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type
  11. 4.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
  13. 4.3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2032)
5 Recombinant Coagulation Factor Ⅷ for Injection Market by Application
  1. 5.1 Recombinant Coagulation Factor Ⅷ for Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application
  6. 5.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application
  10. 5.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2032)
6 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region
  1. 6.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region
  1. 7.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region
  2. 7.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GC Pharma
  2. 8.1.1 GC Pharma Company Information
  3. 8.1.2 GC Pharma Business Overview
  4. 8.1.3 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  6. 8.1.5 GC Pharma Recent Developments
  7. 8.2 Novo Nordisk A/S
  8. 8.2.1 Novo Nordisk A/S Company Information
  9. 8.2.2 Novo Nordisk A/S Business Overview
  10. 8.2.3 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  12. 8.2.5 Novo Nordisk A/S Recent Developments
  13. 8.3 SinoCell Tech
  14. 8.3.1 SinoCell Tech Company Information
  15. 8.3.2 SinoCell Tech Business Overview
  16. 8.3.3 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  18. 8.3.5 SinoCell Tech Recent Developments
  19. 8.4 Baxter
  20. 8.4.1 Baxter Company Information
  21. 8.4.2 Baxter Business Overview
  22. 8.4.3 Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  24. 8.4.5 Baxter Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Hualan Biological
  32. 8.6.1 Hualan Biological Company Information
  33. 8.6.2 Hualan Biological Business Overview
  34. 8.6.3 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  36. 8.6.5 Hualan Biological Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Shanghai Raas Corp
  44. 8.8.1 Shanghai Raas Corp Company Information
  45. 8.8.2 Shanghai Raas Corp Business Overview
  46. 8.8.3 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  48. 8.8.5 Shanghai Raas Corp Recent Developments
  49. 8.9 Shanghai Xinxing Medicine
  50. 8.9.1 Shanghai Xinxing Medicine Company Information
  51. 8.9.2 Shanghai Xinxing Medicine Business Overview
  52. 8.9.3 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  54. 8.9.5 Shanghai Xinxing Medicine Recent Developments
  55. 8.10 Shandong Taibang Biological Products
  56. 8.10.1 Shandong Taibang Biological Products Company Information
  57. 8.10.2 Shandong Taibang Biological Products Business Overview
  58. 8.10.3 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
  60. 8.10.5 Shandong Taibang Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Coagulation Factor Ⅷ for Injection Value Chain Analysis
  2. 9.1.1 Recombinant Coagulation Factor Ⅷ for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Coagulation Factor Ⅷ for Injection Production Mode & Process
  6. 9.2 Recombinant Coagulation Factor Ⅷ for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Coagulation Factor Ⅷ for Injection Distributors
  9. 9.2.3 Recombinant Coagulation Factor Ⅷ for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst